We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02174094
Recruitment Status : Withdrawn (The study was terminated due to recruitment challenges)
First Posted : June 25, 2014
Last Update Posted : September 24, 2015
Sponsor:
Information provided by (Responsible Party):
H. Lundbeck A/S

Tracking Information
First Submitted Date  ICMJE June 2, 2014
First Posted Date  ICMJE June 25, 2014
Last Update Posted Date September 24, 2015
Study Start Date  ICMJE March 2015
Actual Primary Completion Date August 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 24, 2014)
Percent change from baseline to study completion/withdrawal in seizure rate for combined tonic-clonic and clonic seizure rates, based upon a calculation of seizure frequency determined from daily seizure diary counts [ Time Frame: Baseline and from week 0 to week 16 ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 24, 2014)
  • Percent change from baseline to study completion/withdrawal in seizure rate for combined tonic-clonic and clonic seizure rates, based upon a calculation of seizure frequency determined from daily seizure diary counts during 4 weeks of maintenance [ Time Frame: Baseline and from week 4 to week 16 ]
  • Percent change in seizure rate for myoclonic seizures determined from daily seizure diary counts [ Time Frame: Baseline and from week 0 to week 16 ]
  • Percent change in seizure rate for atypical absence seizures determined from daily seizure diary counts [ Time Frame: Baseline and from week 0 to week 16 ]
  • Percent change in seizure rate for complex partial seizures determined from daily seizure diary counts [ Time Frame: Baseline and from week 0 to week 16 ]
  • Percent change in seizure rate for all seizure types determined from daily seizure diary counts [ Time Frame: Baseline and from week 0 to week 16 ]
  • Number of initial treatment responders who returned to their baseline tonic-clonic and clonic seizure rate during the study (an assessment of tachyphylaxis) [ Time Frame: Baseline and from week 0 to week 16 ]
  • Percentage of initial treatment responders who returned to their baseline tonic-clonic and clonic seizure rate during the study (an assessment of tachyphylaxis) [ Time Frame: Baseline and from week 0 to week 16 ]
  • Percent change in seizure rate for myoclonic seizures determined from video EEG [ Time Frame: Baseline and from week 0 to week 16 ]
  • Percent change in seizure rate for atypical absence seizures determined from video EEG [ Time Frame: Baseline and from week 0 to week 16 ]
  • Change in Symptom and Seizure Activity Scale (Investigator and Parent/caregiver versions) [ Time Frame: Baseline and from week 0 to week 16 ]
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Up to Week 32 ]
  • Columbia Suicide Severity Rating Scale (C-SSRS), categorisation based on Columbia Classification Algorithm of Suicide Assessment (C-CASA) categories (1, 2, 3, 4 and 7) for patients aged ≥ 6 years [ Time Frame: Baseline and from week 0 to week 16 ]
  • Number of Participants with Adverse Events of special interest as a Measure of Safety and Tolerability based on dose [ Time Frame: Baseline and Week 32 ]
  • Change in Vineland Adaptive Behaviour Scale (VABS) - all adaptive behavior sub-domains and maladaptive behaviors [ Time Frame: Baseline and from week 0 to week 16 ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
Official Title  ICMJE Multi-site, Prospective, Randomised, Double-blind, Placebo-controlled, Parallel-group, Interventional Study to Evaluate the Efficacy, Safety, and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
Brief Summary The purpose of this study is to investigate the effect on the frequency of tonic-clonic and clonic seizures of clobazam as adjunctive therapy compared to placebo after 16 weeks of treatment in paediatric patients aged ≥1 to ≤16 years with Dravet Syndrome.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Dravet Syndrome
Intervention  ICMJE
  • Drug: Clobazam
    Other Name: Onfi®
  • Drug: Placebo
Study Arms  ICMJE
  • Experimental: Clobazam
    Clobazam - 1.0, 1.5 or 2.0 mg/kg/day (maximum 60 or 80 mg/day) twice daily (BID); Clobazam oral suspension 2.5 mg/mL, clobazam scored tablets 10 mg, orally
    Intervention: Drug: Clobazam
  • Placebo Comparator: Placebo
    Placebo to clobazam oral suspension 2.5 mg/mL and placebo to clobazam scored tablets 10 mg, orally
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: September 23, 2015)
0
Original Estimated Enrollment  ICMJE
 (submitted: June 24, 2014)
54
Actual Study Completion Date  ICMJE August 2015
Actual Primary Completion Date August 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Onset of seizures in the first year of life
  • History of fever-induced prolonged seizures as determined by the Investigator
  • These may include prolonged (approximately 15 minutes or longer) hemi-clonic seizures
  • Multiple seizure types which may include:

    • generalised tonic-clonic (required for inclusion)
    • clonic (required for inclusion)
    • myoclonic jerks/seizures
    • history of normal development prior to seizure onset followed by development delay or regression after seizure onset
    • abnormal EEG consistent with Dravet Syndrome 2. The patient has a history of approximately 2 tonic-clonic or clonic seizures in 2 weeks 3. The patient is treated with at least 1 but no more than 3 antiepileptic drugs (AEDs) [Vagal Nerve Stimulator (VNS) and ketogenic diet will not be considered an AED] 4. Patient has at least 2 seizures during the Baseline Period of either 2 or 4 weeks

Exclusion Criteria:

  1. The patient is taking stiripentol, verapamil, or felbatol. If patients have taken these drugs in the past, they need to have been off drug for 5 half-lives
  2. The patient is taking a sodium channel blocker including, but not limited to, phenytoin, fosphenytoin, carbamazepine, oxcarbamazepine, lamotrigine, lacosamide, and rufinamide. If patients have taken these drugs in the past, they need to have been off drug for 5 half-lives
  3. The patient is on cannabidiol, medical marijuana, or any drug that contains cannabinoids
  4. The patient has received chronic treatment (≥2 weeks for any indication) with a benzodiazepine within at least 5 half-lives prior to screening. Rescue therapy for prolonged seizures is allowed
  5. The patient has received clobazam within 3 months prior to the Screening Visit. If the patient has received clobazam in the past, discontinuation must not have been for adverse events or lack of efficacy

Other protocol-defined inclusion and exclusion criteria may apply.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 1 Year to 16 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Mexico,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02174094
Other Study ID Numbers  ICMJE 14362A
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party H. Lundbeck A/S
Original Responsible Party Same as current
Current Study Sponsor  ICMJE H. Lundbeck A/S
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Email contact via H. Lundbeck A/S LundbeckClinicalTrials@lundbeck.com
PRS Account H. Lundbeck A/S
Verification Date September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP